|Trade names||Cyklokapron, others|
|AHFS/Drugs.com||FDA Professional Drug Information|
|by mouth, injection|
|Biological half-life||3.1 h|
|Chemical and physical data|
|Molar mass||157.21 g/mol|
|3D model (Jmol)|
Tranexamic acid (TXA) is a medication used to treat or prevent excessive blood loss from major trauma, post partum bleeding, surgery, tooth removal, nose bleeds, and heavy menstruation. It is also used for hereditary angioedema. It is taken either by mouth or injection into a vein.
Side effects are rare. Some include changes in color vision, blood clots and allergic reactions. Greater caution is recommended in people with kidney disease. Tranexamic appears to be safe for use during pregnancy and breastfeeding. Tranexamic acid is in the antifibrinolytic family of medications.
Tranexamic acid was discovered in 1962 by Utako Okamoto. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Tranexamic acid is available as a generic medication. The wholesale cost in the developing world is about 4.38 to 4.89 USD for a course of treatment. In the United States a course of treatment costs 100 to 200 USD.
Tranexamic acid is frequently used following major trauma. Tranexamic acid is used to prevent and treat blood loss in a variety of situations, such as dental procedures for hemophiliacs, heavy menstrual bleeding, and surgeries with high risk of blood loss.
Tranexamic acid is used to treat heavy menstrual bleeding. When taken by mouth it both safely and effectively treats regularly occurring heavy menstrual bleeding. Another study demonstrated that the dose does not need to be adjusted in females who are between ages 12 and 16.
A 2017 trial found that it decreased the risk of death from bleeding from 1.9% to 1.5% in women with postpartum bleeding. The benefit was greater when the medication was given within three hours.
- Tranexamic acid is used in orthopedic surgery to reduce blood loss, to the extent of reducing or altogether abolishing the need for perioperative blood collection. It is of proven value in clearing the field of surgery and reducing blood loss when given before or after surgery. Drain and number of transfusions are reduced.
- In surgical corrections of craniosynostosis in children it reduces the need for blood transfusions.
- In spine surgery, e.g. scoliosis correction with posterior spinal fusion using instrumentation, to prevent excessive blood loss.
- In cardiac surgery, both with and without cardiopulmonary bypass e.g. coronary artery bypass surgery, it is used to prevent excessive blood loss. It replaces aprotinin.
In the United States, tranexamic acid is FDA approved for short-term use in people with severe bleeding disorders who are about to have dental surgery. Tranexamic acid is used for a short period of time before and after the surgery to prevent major blood loss and decrease the need for blood transfusions. In people with hemophilia, combinations of tranexamic acid and factor VII or IX have effectively decreased blood loss and the need for transfusions after dental surgery In one person with mild hemophilia, a combination of tranexamic acid and desmopressin effectively stopped bleeding
Tranexamic acid is used in dentistry in the form of a 5% mouth rinse after extractions or surgery in patients with prolonged bleeding time, e.g. from acquired or inherited disorders.
- In obstetrics, tranexamic acid is used after delivery to reduce bleeding, often with syntocinon/oxytocin and fundal massage. Since 2010, the WOMAN (World Maternal Antifibrinolytic) trial has been in progress worldwide to establish the efficacy of the drug to arrest postpartum haemorrhage (PPH) in 15 000 women, due to be completed in 2016. Since the drug can be administered orally, it has great potential to reduce maternal mortality rates in developing countries where primary healthcare is often unavailable.
- In hereditary angioedema
- In hereditary hemorrhagic telangiectasia - Tranexamic acid has been shown to reduce frequency of epistaxis in patients suffering severe and frequent nosebleed episodes from hereditary hemorrhagic telangiectasia.
- In melasma - tranexamic acid is sometimes used in skin whitening as a topical agent, injected into a lesion, or taken by mouth, both alone and as an adjunct to laser therapy; as of 2017 its safety seemed reasonable but its efficacy for this purpose was uncertain because there had been no large scale randomized controlled studies nor long term follow-up studies.
- In hyphema - Tranexamic acid has been shown to be effective in reducing risk of secondary hemorrhage outcomes in patients with traumatic hyphema.[needs update]
Common side effects include:
- Headaches (50.4 - 60.4%)
- Back aches (20.7 - 31.4%)
- Nasal sinus problem (25.4%)
- Abdominal pain (12 - 19.8%)
- Diarrhea (12.2%)
- Fatigue (5.2%)
- Anemia (5.6%)
Rare side effects include:
- Tranexamic acid is categorized as pregnancy category B. No harm has been found in animal studies.
- Small amounts appears in breast milk if taken during lactation. If it is required for other reasons, breastfeeding may be continued.
- Tranexamic acid is also not indicated for postmenopausal women and geriatrics.
- In kidney impairment, tranexamic acid is not well studied. However, due to the fact that it is 95% excreted unchanged in the urine, it should be dose adjusted in patients with renal impairment.
- In liver impairment, dose change is not needed as only a small amount of the drug is metabolized through the liver.
Mechanism of action
Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen or plasmin. This prevents plasmin from binding to and degrading fibrin and preserves the framework of fibrin's matrix structure. Tranexamic acid has roughly eight times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid.
Society and culture
TXA was discovered in 1962 by Utako Okamoto. It has been included in the WHO list of essential medicines. TXA is inexpensive and treatment would be considered highly cost effective in high, middle and low income countries.
Tranexamic acid is marketed in the U.S. and Australia in tablet form as Lysteda and in Australia and Jordan it is marketed in an IV form and tablet form as Cyklokapron, in the UK as Cyclo-F and Femstrual, in Asia as Transcam, in Bangladesh as Traxyl, in India as Pause, in South America as Espercil, in Japan as Nicolda, in France and Romania as Exacyl and in Egypt as Kapron. In the Philippines, its capsule form is marketed as Hemostan and In Israel as Hexakapron.
The U.S. Food and Drug Administration (FDA) approved tranexamic acid oral tablets (brand name Lysteda) for treatment of heavy menstrual bleeding on 13 November 2009.
In March 2011 the status of tranexamic acid for treatment of heavy menstrual bleeding was changed in the UK, from PoM (Prescription only Medicines) to P (Pharmacy Medicines) and became available over the counter in UK pharmacies under the brand names of Cyklo-F and Femstrual, initially exclusively for Boots pharmacy, which has sparked some discussion about availability. (In parts of Europe it had then been available OTC for over a decade.) Regular liver function tests are recommended when using tranexamic acid over a long period of time.
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 170. ISBN 9780857111562.
- Shakur, Haleema; Roberts, Ian; Fawole, Bukola (April 2017). "Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial". The Lancet. doi:10.1016/S0140-6736(17)30638-4.
- "Cyklokapron Tablets - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. September 2016. Retrieved 14 December 2016.
- "Tranexamic Acid Injection - FDA prescribing information, side effects and uses". www.drugs.com. Retrieved 14 December 2016.
- "Tranexamic acid Use During Pregnancy | Drugs.com". www.drugs.com. Retrieved 14 December 2016.
- Geoff Watts (2016). "Obituary Utako Okamoto". The Lancet. 387 (10035): 2286. doi:10.1016/S0140-6736(16)30697-3.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. X. ISBN 9781284057560.
- "Tranexamic Acid". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- Binz, S; McCollester, J; Thomas, S; Miller, J; Pohlman, T; Waxman, D; Shariff, F; Tracy, R; Walsh, M (2015). "CRASH-2 Study of Tranexamic Acid to Treat Bleeding in Trauma Patients: A Controversy Fueled by Science and Social Media.". Journal of blood transfusion. 2015: 874920. PMC . PMID 26448897. doi:10.1155/2015/874920.
- Melvin, JS; Stryker, LS; Sierra, RJ (22 October 2015). "Tranexamic Acid in Hip and Knee Arthroplasty.". The Journal of the American Academy of Orthopaedic Surgeons. 23: 732–40. PMID 26493971. doi:10.5435/JAAOS-D-14-00223.
- Tengborn, L; Blombäck, M; Berntorp, E (February 2015). "Tranexamic acid--an old drug still going strong and making a revival.". Thrombosis research. 135 (2): 231–42. PMID 25559460. doi:10.1016/j.thromres.2014.11.012.
- Cherkas, David (Nov 2011). "Traumatic Hemorrhagic Shock: Advances In Fluid Management". Emergency Medicine Practice. 13 (11).
- "Drug will save lives of accident victims, says study". BBC News. 2010. Retrieved 3 June 2016.
- Napolitano, Lena M.; Cohen, Mitchell J.; Cotton, Bryan A.; Schreiber, Martin A.; Moore, Ernest E. (2013). "Tranexamic acid in trauma". Journal of Trauma and Acute Care Surgery. 74 (6): 1575–86. PMID 23694890. doi:10.1097/TA.0b013e318292cc54.
- "Lysteda (tranexamic acid) Package Insert" (PDF). accessdata.FDA.gov. Retrieved 2 November 2015.
- Lukes, AS; Moore, KA; Muse, KN (2010). "Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial". Obstet Gynecol. 116 (4): 865–875. PMID 20859150. doi:10.1097/AOG.0b013e3181f20177.
- RCPCH. "Evidence Statement Major trauma and the use of tranexamic acid in children Nov 2012" (PDF). Retrieved 17 December 2012.
- Sethna, N. F.; Zurakowski, D; Brustowicz, R. M.; Bacsik, J; Sullivan, L. J.; Shapiro, F (2005). "Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery". Anesthesiology. 102 (4): 727–32. PMID 15791100. doi:10.1097/00000542-200504000-00006.
- "Cyklokapron (tranexamic acid) Product Information" (PDF). Retrieved 3 November 2015.
- Forbes CD, Barr RD, Reid G; et al. (1972). "Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease". Br Med J. 2 (5809): 311–313. doi:10.1136/bmj.2.5809.311.
- Shankar S & Lee R (1984). "DDAVP and tranexamic acid for dental extractions in a mild hemophiliac". Br Dent J. 156 (12): 450–452. doi:10.1038/sj.bdj.4805387.
- "Protocol 09PRT/4179:Tranexamic acid for the treatment of postpartum haemorrhage: an international, randomised, double blind, placebo controlled trial (the WOMAN Trial)". The Lancet. Elsevier Limited. n.d. Retrieved 3 June 2016.
- Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-06911-5.[page needed]
- Klepfish, A; Berrebi, A; Schattner, A (2001). "Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia". Archives of Internal Medicine. 161 (5): 767. PMID 11231712. doi:10.1001/archinte.161.5.767.
- Zhou, LL; Baibergenova, A (27 February 2017). "Melasma: systematic review of the systemic treatments.". International Journal of Dermatology. PMID 28239840. doi:10.1111/ijd.13578.
- Taraz, M; Niknam, S; Ehsani, AH (30 January 2017). "Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies.". Dermatologic therapy: e12465. PMID 28133910. doi:10.1111/dth.12465.
- Gharaibeh, Almutez; Savage, Howard I; Scherer, Roberta W; Goldberg, Morton F; Lindsley, Kristina (2011). "Medical interventions for traumatic hyphema". Cochrane Database of Systematic Reviews (1): CD005431. PMC . PMID 21249670. doi:10.1002/14651858.CD005431.pub2.
- "Tranexamic Acid use while Breastfeeding". www.drugs.com. 7 Nov 2014. Retrieved 27 May 2016.
- "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.
- Guerriero, Carla; Cairns, John; Perel, Pablo; Shakur, Haleema; Roberts, Ian; Crash 2 Trial, Collaborators (2011). "Cost-Effectiveness Analysis of Administering Tranexamic Acid to Bleeding Trauma Patients Using Evidence from the CRASH-2 Trial". PLoS ONE. 6 (5): e18987. Bibcode:2011PLoSO...618987G. PMC . PMID 21559279. doi:10.1371/journal.pone.0018987.
- Tranexamic Acid to be available OtC[full citation needed]
- In defence of multiple pharmacies[full citation needed]
- Allen, Helen (June 13, 2012). "Tranexamic acid for bleeding". Patient UK.